Discordance across phenotypic and molecular methods for drug susceptibility testing of drug-resistant Mycobacterium tuberculosis isolates in a low TB incidence country

PLoS ONE

Volumn 11, Issue 4, 2016, Pages

  Ahmad, Suhail ^a   Mokaddas, Eiman ^a,b   Al Mutairi, Noura ^a   Eldeen, Hanaa S ^b   Mohammadi, Shirin ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

^b Kuwait National TB Reference Laboratory   (Kuwait)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; RIFAMPICIN; STREPTOMYCIN; BACTERIAL DNA; TUBERCULOSTATIC AGENT;

ACCURACY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL MUTATION; BACTERIUM ISOLATE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; HUMAN; HUMAN TISSUE; INCIDENCE; INTERMETHOD COMPARISON; KUWAIT; LABORATORY DEVICE; MIGRANT WORKER; MOLECULAR TYPING; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; PHENOTYPE; SEQUENCE ANALYSIS; DRUG EFFECTS; GENETICS; GENOTYPE; ISOLATION AND PURIFICATION; MICROBIOLOGY; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; DNA, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GENOTYPE; HUMANS; INCIDENCE; KUWAIT; MYCOBACTERIUM TUBERCULOSIS; PHENOTYPE; SEQUENCE ANALYSIS, DNA; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84978091943     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0153563     Document Type: Article

References (71)

1. World Health Organization. Global tuberculosis report 2015. WHO/HTM/TB/2015.22, Geneva, Switzerland: WHO, 2015.
2. Wright A, Zignol M, Van Deun A, Falzon D, Gerdes SR, Feldman K, et al. Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet 2009; 373: 1861-1873. doi: 10.1016/S0140-6736(09)60331-7 PMID: 19375159
3. World Health Organization. Drug-resistant TB, surveillance and response: supplement to global tuberculosis report 2014. WHO/HQ/TB/2014.12, Geneva, Switzerland: WHO, 2014.
4. Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, Moll AP, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infectious Diseases 2009; 9: 153-161. doi: 10.1016/S1473-3099(09)70041-6 PMID: 19246019
5. Gandhi NR, Andrews JR, Brust JCM, Montreuil R, Weissman D, Heo M, et al. Risk factors for mortality among MDR-and XDR-TB patients in a high HIV prevalence setting. Int J Tuberc Lung Dis 2012; 16: 90-97. doi: 10.5588/ijtld.11.0153 PMID: 22236852
6. Ahmad S, Mokaddas E. Current status and future trends in the diagnosis and treatment of drug-susceptible and multidrug-resistant tuberculosis. J Infect Pub Health 2014; 7: 75-91.
7. Jacobson KR, Tierney DB, Jeon CY, Mitnick CD, Murray MB. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 2010; 51: 6-14. doi: 10.1086/653115 PMID: 20504231
8. Dalton T, Cegielski P, Akksilp S, Asencios L, Campos Caoili J, Cho SN, et al. Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet 2012; 380: 1406-1417. doi: 10.1016/S0140-6736(12)60734-X PMID: 22938757
9. Hoffner S. Unexpected high levels of multidrug-resistant tuberculosis present new challenges for tuberculosis control. Lancet 2012; 380: 1367-1369. doi: 10.1016/S0140-6736(12)61069-1 PMID: 22938756
10. Zignol M, Dara M, Dean AS, Falzon D, Dadu A, Kremer K, et al. Drug-resistant tuberculosis in the WHO European Region: an analysis of surveillance data. Drug Resist Updat 2013; 16: 108-115. doi: 10. 1016/j.drup.2014.02.003 PMID: 24631052
11. Drobniewski F, Nikolayevskyy V, Balabanova Y, Bang D, Papaventsis D. Diagnosis of tuberculosis and drug resistance: what can new tools bring us? Int J Tuberc Lung Dis 2012; 16: 860-870. doi: 10.5588/ijtld.12.0180 PMID: 22687497
12. World Health Organization. Guidelines for surveillance of drug resistance in tuberculosis. WHO and the International Union Against Tuberculosis and Lung Disease. Int J Tuberc Lung Dis 1998; 2: 72-89. PMID: 9562116
13. Palomino JC, Martin A, Von Groll A, Portaels F. Rapid culture-based methods for drug-resistance detection in Mycobacterium tuberculosis. J Microbiol Methods 2008; 75: 161-166. doi: 10.1016/j. mimet.2008.06.015 PMID: 18627779
14. World Health Organization. Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB): policy statement. WHO, Geneva, Switzertland, 2008.
15. Van Deun A, Martin A, Palomino JC. Diagnosis of drug-resistant tuberculosis: reliability and rapidity of detection. Int J Tuberc Lung Dis 2010; 14: 131-140. PMID: 20074402
16. Siddiqi SH. BACTEC 460TB system and procedure manual, revision D. Becton Dickinson Microbiology Systems, Sparks, MD, USA, 1995.
17. Tortoli E, Benedetti M, Fontanelli A, Tullia Simonetti M. Evaluation of automated BACTEC MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to four major antituberculous drugs: comparison with the radiometric BACTEC 460TB method and the agar plate method of proportion. J Clin Microbiol 2002; 40: 607-610. PMID: 11825978
18. Scarparo C, Ricordi P, Ruggiero G, Piccoli P. Evaluation of the fully automated BACTEC MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide, streptomycin, isoniazid, rifampin, and ethambutol and comparison with the radiometric BACTEC 460TB method. J Clin Microbiol 2004; 42: 1109-1114. PMID: 15004061
19. Garrigó M, Aragón LM, Alcaide F, Borrell S, Cardeñosa E, Galán JJ, et al. Multicenter laboratory evaluation of the MB/BacT Mycobacterium detection system and the BACTEC MGIT 960 system in comparison with the BACTEC 460TB system for susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol 2007; 45: 1766-1770. PMID: 17442793
20. Piersimoni C, Olivieri A, Benacchio L, Scarparo C. Current perspectives on drug susceptibility testing of Mycobacterium tuberculosis complex: the automated nonradiometric systems. J Clin Microbiol 2006; 44: 20-28. PMID: 16390942
21. Van Deun A, Barrera L, Bastian I, Fattorini L, Hoffmann H, Kam KM, et al. Mycobacterium tuberculosis strains with highly discordant rifampin susceptibility test results. J Clin Microbiol 2009; 47: 3501-3506. doi: 10.1128/JCM.01209-09 PMID: 19759221
22. Angra PK, Taylor TH, Iademarco MF, Metchock B, Astles JR, Ridderhof JC. Performance of tuberculosis drug susceptibility testing in U.S. laboratories from 1994 to 2008. J Clin Microbiol 2012; 50: 1233-1239. doi: 10.1128/JCM.06479-11 PMID: 22301024
23. Rigouts L, Gumusboga M, de Rijk WB, Nduwamahoro E, Uwizeye C, de Jong B, et al. Rifampin resistance missed in automated liquid culture system for Mycobacterium tuberculosis isolates with specific rpoB mutations. J Clin Microbiol 2013; 51: 2641-2645 doi: 10.1128/JCM.02741-12 PMID: 23761146
24. Van Deun A, Aung KJ, Bola V, Lebeke R, Hossain MA, de Rijk WB, et al. Rifampin drug resistance tests for tuberculosis: challenging the gold standard. J Clin Microbiol 2013; 51: 2633-2640. doi: 10. 1128/JCM.00553-13 PMID: 23761144
25. Banu S, Rahman SM, Khan MS, Ferdous SS, Ahmed S, Gratz J, et al. Discordance across several methods for drug susceptibility testing of drug-resistant Mycobacterium tuberculosis isolates in a single laboratory. J Clin Microbiol 2014; 52: 156-163. doi: 10.1128/JCM.02378-13 PMID: 24172155
26. Ocheretina O, Escuyer VE, Mabou MM, Royal-Mardi G, Collins S, Vilbrun SC, et al. Correlation between genotypic and phenotypic testing for resistance to rifampin in Mycobacterium tuberculosis clinical isolates in Haiti: investigation of cases with discrepant susceptibility results. PLoS One 2014; 9: e90569. doi: 10.1371/journal.pone.0090569 PMID: 24599230
27. Yakrus MA, Driscoll J, Lentz AJ, Sikes D, Hartline D, Metchock B, Starks AM. Concordance between molecular and phenotypic testing of Mycobacterium tuberculosis complex isolates for resistance to rifampin and isoniazid in the United States. J Clin Microbiol 2014; 52: 1932-1937. doi: 10.1128/JCM. 00417-14 PMID: 24648563
28. World Health Organization. Rapid implementation of the Xpert MTB/RIF diagnostic test. WHO/HTM/TB/2011.2 World Health Organization, Geneva, Switzertland, 2011.
29. Kurbatova EV, Cavanaugh JS, Shah NS, Wright A, Kim H, Metchock B, et al. Rifampicin-resistant Mycobacterium tuberculosis: susceptibility to isoniazid and other anti-tuberculosis drugs. Int J Tuberc Lung Dis 2012; 16: 355-357. doi: 10.5588/ijtld.11.0542 PMID: 22640449
30. van der Spuy GD, Jacobson KR, Roscher M, Streicher EM, Musekiwa A, Coetzee GJ, et al. Rise in rifampicin-monoresistant tuberculosis in Western Cape, South Africa. Int J Tuberc Lung Dis 2012; 16: 196-202. doi: 10.5588/ijtld.11.0116 PMID: 22236920
31. Velayati AA, Farnia P, Mozafari M, Sheikholeslami MF, Karahrudi MA, Tabarsi P, et al. High prevelance of rifampin-monoresistant tuberculosis: a retrospective analysis among Iranian pulmonary tuberculosis patients. Am J Trop Med Hyg 2014; 90: 99-105. doi: 10.4269/ajtmh.13-0057 PMID: 24189362
32. Telenti A, Imboden P, Marchesi F, Lowrie D, Cole S, Colston MJ, et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 1993; 341: 647-650. PMID: 8095569
33. Al-Mutairi N, Ahmad S, Mokaddas E. Performance comparison of four methods for rapid detection of multidrug-resistant Mycobacterium tuberculosis strains. Int J Tuberc Lung Dis 2011; 15: 110-115 PMID: 21276306
34. Campbell PJ, Morlock GP, Sikes RD, Dalton TL, Metchock B, Starks AM, et al. Molecular detection of mutations associated with first-and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2011; 55: 2032-2041. doi: 10.1128/AAC.01550-10 PMID: 21300839
35. Alonso M, Palacios JJ, Herranz M, Penedo A, Menéndez A, Bouza E, García de Viedma D. Isolation of Mycobacterium tuberculosis strains with a silent mutation in rpoB leading to potential misassignment of resistance category. J Clin Microbiol 2011; 49:2688-2690. doi: 10.1128/JCM.00659-11 PMID: 21562104
36. Mokaddas E, Ahmad S, Eldeen HS, Al-Mutairi N. Discordance between Xpert MTB/RIF assay and Bactec MGIT 960 culture system for detection of rifampin-resistant Mycobacterium tuberculosis isolates in a country with a low tuberculosis (TB) incidence. J Clin Microbiol 2015; 53: 1351-1354. doi: 10.1128/JCM.03412-14 PMID: 25609730
37. Liu CH, Li HM, Lu N, Wang Q, Hu YL, Yang X, et al. Genomic sequence based scanning for drug resistance-associated mutations and evolutionary analysis of multidrug-resistant and extensively drugresistant Mycobacterium tuberculosis. J Infect 2012; 65: 412-422. doi: 10.1016/j.jinf.2012.06.007 PMID: 22728171
38. Köser CU, Bryant JM, Becq J, Török ME, Ellington MJ, Marti-Renom MA, et al. Whole-genome sequencing for rapid susceptibility testing of M. tuberculosis. N Engl J Med 2013; 369: 290-292. doi: 10.1056/NEJMc1215305 PMID: 23863072
39. Zhang H, Li D, Zhao L, Fleming J, Lin N, Wang T, et al. Genome sequencing of 161 Mycobacterium tuberculosis isolates from China identifies genes and intergenic regions associated with drug resistance. Nat Genet 2013; 45: 1255-1260. doi: 10.1038/ng.2735 PMID: 23995137
40. Witney AA, Gould KA, Arnold A, Coleman D, Delgado R, Dhillon J, et al. Clinical application of wholegenome sequencing to inform treatment for multidrug-resistant tuberculosis cases. J Clin Microbiol 2015; 53: 1473-1483 doi: 10.1128/JCM.02993-14 PMID: 25673793
41. Brown AC, Bryant JM, Einer-Jensen K, Holdstock J, Houniet DT, Chan JZ, et al. Rapid whole-genome sequencing of Mycobacterium tuberculosis isolates directly from clinical samples. J Clin Microbiol 2015; 53: 2230-2237. doi: 10.1128/JCM.00486-15 PMID: 25972414
42. Walker TM, Kohl TA, Omar SV, Hedge J, Del Ojo Elias C, Bradley P, et al. Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study. Lancet Infect Dis 2015; 15: 1193-1202. doi: 10.1016/S1473-3099(15)00062-6 PMID: 26116186
43. Ramaswamy S, Musser JM. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuberc Lung Dis 1998; 79: 3-29.
44. Ahmad S, Mokaddas E. Recent advances in the diagnosis and treatment of multidrug-resistant tuberculosis. Resp Med 2009; 103: 1777-1790.
45. Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis: update 2015. Int J Tuberc Lung Dis 2015; 19: 1276-1289. doi: 10.5588/ijtld.15.0389 PMID: 26467578
46. Mokaddas E, Ahmad S, Samir I. Secular trends in susceptibility patterns of Mycobacterium tuberculosis isolates in Kuwait, 1996-2005. Int J Tuberc Lung Dis 2008; 12: 319-325. PMID: 18284839
47. Becton, Dickinson and Company. BACTEC MGIT-960 SIRE kit for the antimycobacterial susceptibility testing of Mycobacterium tuberculosis. Becton, Dickinson & Company, Sparks, MD, USA.
48. Mokaddas E, Ahmad S. Development and evaluation of a multiplex PCR for rapid detection and differentiation of Mycobacterium tuberculosis complex members from non-tuberculous mycobacteria. Jap J Infect Dis 2007; 60:140-144.
49. Ahmad S, Al-Mutairi NM, Mokaddas E. Variations in the occurrence of specific rpoB mutations in rifampicin-resistant Mycobacterium tuberculosis strains isolated from patients of different ethnic groups in Kuwait. Ind J Med Res 2012; 135: 756-762.
50. Ahmad S, Mokaddas E. Contribution of AGC to ACC and other mutations at codon 315 of the katG gene in isoniazid-resistant Mycobacterium tuberculosis isolates from the Middle East. Int J Antimicrob Agents 2004; 23: 473-479. PMID: 15120726
51. Ahmad S, Jaber AA, Mokaddas E. Frequency of embB codon 306 mutations in ethambutol-susceptible and-resistant clinical Mycobacterium tuberculosis isolates in Kuwait. Tuberculosis (Edinburgh) 2007; 87: 123-129.
52. Abal AT, Ahmad S, Mokaddas E. Variations in the occurrence of the S315T mutation within the katG gene in isoniazid-resistant clinical Mycobacterium tuberculosis isolates from Kuwait. Microb Drug Resist 2002; 8: 99-105 PMID: 12118524
53. Hillemann D, Gerdes RS, Richter E. Evaluation of GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 2007; 45: 2635-2640. PMID: 17537937
54. Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med 2012; 9: e1001300 PMID: 22952439
55. van Ingen J, Aarnoutse R, de Vries G, Boeree MJ, van Soolingen D. Low-level rifampicin-resistant Mycobacterium tuberculosis strains raise a new therapeutic challenge. Int J Tuberc Lung Dis 2011; 15: 990-992. doi: 10.5588/ijtld.10.0127 PMID: 21682979
56. Van Deun A, Aung KJ, Hossain A, de Rijk P, Gumusboga M, Rigouts L, et al. Disputed rpoB mutations can frequently cause important rifampicin resistance among new tuberculosis patients. Int J Tuberc Lung Dis 2015; 19: 185-190. doi: 10.5588/ijtld.14.0651 PMID: 25574917
57. Bemer P, Palicova F, Rüsch-Gerdes S, Drugeon HB, Pfyffer GE. Multicenter evaluation of fully automated BACTEC Mycobacteria Growth Indicator Tube 960 system for susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol 2002; 40: 150-154. PMID: 11773109
58. Ramaswamy S, Reich R, Dou S, Jasperse L, Pan X, Wanger A, et al. Single nucleotide polymorphisms in genes associated with isoniazid resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003; 47: 1241-1250. PMID: 12654653
59. Machado D, Couto I, Perdigão J, Rodrigues L, Portugal I, Baptista P, et al. Contribution of efflux to the emergence of isoniazid and multidrug resistance in Mycobacterium tuberculosis PLoS One 2012; 7: e34538. doi: 10.1371/journal.pone.0034538 PMID: 22493700
60. Zhang Y, YewWW(2009) Mechanisms of drug resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2009; 13: 1320-1330. PMID: 19861002
61. Juréen P, Angeby K, Sturegård E, Chryssanthou E, Giske CG, Werngren J, et al. Wild-type MIC distributions for aminoglycoside and cyclic polypeptide antibiotics used for treatment of Mycobacterium tuberculosis infections. J Clin Microbiol 2010; 48: 1853-1858. doi: 10.1128/JCM.00240-10 PMID: 20237102
62. Spies FS, da Silva PE, Ribeiro MO, Rossetti ML, Zaha A. Identification of mutations related to streptomycin resistance in clinical isolates of Mycobacterium tuberculosis and possible involvement of efflux mechanism. Antimicrob Agents Chemother 2008; 52: 2947-2949. doi: 10.1128/AAC.01570-07 PMID: 18541729
63. Spies FS, Ribeiro AW, Ramos DF, Ribeiro MO, Martin A, Palomino JC, et al. Streptomycin resistance and lineage-specific polymorphisms in Mycobacterium tuberculosis gidB gene. J Clin Microbiol 2011; 49: 2625-2630. doi: 10.1128/JCM.00168-11 PMID: 21593257
64. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al. Treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-662. PMID: 12588714
65. Krüüner A, Yates MD, Drobniewski FA. Evaluation of MGIT 960-based antimicrobial testing and determination of critical concentrations of first-and second-line antimicrobial drugs with drug-resistant clinical strains of Mycobacterium tuberculosis. J Clin Microbiol 2006; 44:811-818. PMID: 16517859
66. Cambau E, Viveiros M, Machado D, Raskine L, Ritter C, Tortoli E, et al. Revisiting susceptibility testing in MDR-TB by a standardized quantitative phenotypic assessment in a European multicentre study. J Antimicrob Chemother 2015; 70: 686-696. doi: 10.1093/jac/dku438 PMID: 25587993
67. Madison B, Robinson-Dunn B, George I, Gross W, Lipman H, Metchock B, et al. Multicenter evaluation of ethambutol susceptibility testing of Mycobacterium tuberculosis by agar proportion and radiometric methods. J Clin Microbiol 2002; 40: 3976-3979. PMID: 12409361
68. Safi H, Sayers B, Hazbón MH, Alland D. Transfer of embB codon 306 mutations into clinical Mycobacterium tuberculosis strains alters susceptibility to ethambutol, isoniazid, and rifampin. Antimicrob Agents Chemother 2008; 52: 2027-2034. doi: 10.1128/AAC.01486-07 PMID: 18378710
69. Plinke C, Walter K, Aly S, Ehlers S, Niemann S. Mycobacterium tuberculosis embB codon 306 mutations confer moderately increased resistance to ethambutol in vitro and in vivo. Antimicrob Agents Chemother 2011; 55: 2891-2896. doi: 10.1128/AAC.00007-10 PMID: 21444710
70. Starks AM, Gumusboga A, Plikaytis BB, Shinnick TM, Posey JE. Mutations at embB codon 306 are an important molecular indicator of ethambutol resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2009; 53: 1061-1066. doi: 10.1128/AAC.01357-08 PMID: 19104018
71. Ramaswamy S, Amin AG, Koksel S, Stager CE, Dou S-J, et al. Molecular genetic analysis of nucleotide polymorphisms associated with ethambutol resistance in human isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2000; 44: 326-336. PMID: 10639358